Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain
Biotech
Bayer scraps ph.1-stage hypertension, neuropathic pain drugs
Bayer has removed a protein therapeutic for hypertension and a treatment for diabetic neuropathic pain from its phase 1 pipeline.
James Waldron
May 12, 2026 5:07am
Eli Lilly sidelines pain prospect in another pipeline shift
Oct 30, 2025 2:19pm
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
AstraZeneca culls neuroscience meds in Q1 clear-out
Apr 29, 2025 7:08am
Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset
Apr 16, 2025 2:55pm
Novo Holdings-backed SiteOne charges up with $100M financing
Dec 18, 2024 7:00am
